American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

The 23rd edition of the Biogen Half Marathon presented by Momentum Multiply will be hosted by Bedfordview Country Club Athletics on January 12, 2025. The Dis-Chem Half Marathon has relaunched to ...